Pedro Ruiz-Esteban

Dr. Pedro Ruiz-Esteban


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
DHDomingo Hernandez
Domingo Hernandez
AEAna Espejo-Gil
Ana Espejo-Gil
MBM Rosa Bernal-Lopez
M Rosa Bernal-Lopez
JMJose Mancera-Romero
Jose Mancera-Romero
ABAntonio J Baca-Osorio
Antonio J Baca-Osorio
RHRicardo Gómez Huelgas
Ricardo Gómez Huelgas
Background: Increasing evidence suggests a mechanistic link between the glycemic environment and renal and cardiovascular events, even below the threshold for diabetes. We aimed to assess the association between HbA1c and chronic kidney disease (CKD) and cardiovascular disease (CVD). Methods: A cross-sectional study involving a random representative sample of 2270 adults from southern Spain (Malaga) was undertaken. We measured HbA1c, serum creatinine and albuminuria in fasting blood and urine samples. Results: Individuals without diabetes in the upper HbA1c tertile had an unfavorable cardiovascular and renal profile and shared certain clinical characteristics with the patients with diabetes. Overall, a higher HbA1c concentration was strongly associated with CKD or CVD after adjustment for traditional risk factors. The patients with known diabetes had a 2-fold higher odds of CKD or CVD. However, when both parameters were introduced in the same model, the HbA1c concentration was only significantly associated with clinical endpoints (OR: 1.4, 95% CI, 1.1-1.6, P = 0.002). An increase in HbA1c of one percentage point was associated with a 30% to 40% increase in the rate of CKD or CVD. This relationship was apparent in persons with and without known diabetes. ROC curves illustrated that a HbA1c of 37 mmol/mol (5.5%) was the optimal value in terms of sensitivity and specificity for predicting endpoints in this population. Conclusion: HbA1c levels were associated with a higher prevalence of CKD and CVD cross-sectionally, regardless of diabetes status. These data support the value of HbA1c as a marker of cardiovascular and renal disease in the general population.

27 September 2014 in Transplantation
Verified
Journal Article
Closed access
DHDomingo Hernandez
Domingo Hernandez
PNPablo Castro de la Nuez
Pablo Castro de la Nuez
AMAlfonso Muriel
Alfonso Muriel
PRPedro Ruiz-Esteban
Pedro Ruiz-Esteban
MGMiguel González-Molina
Miguel González-Molina
MAManuel Alonso
Manuel Alonso
Background Prediction of mortality in wait-listed patients for kidney transplantation (KT) has not been well elucidated. We assessed whether application of the Charlson comorbidity index (CCI) and other uremia-related comorbidities, not included in the CCI, were associated with mortality in these patients. Methods We included 3851 adult patients from the Andalusian Registry who were placed on the waiting list for KT during the study period (1984–2012). A total of 1975 patients received a successful KT and were censored at that point, whereas 1876 were on the waiting list at any time. Multivariate Cox proportional regression analysis and competing risk models, both of which included a propensity score for factors leading to KT, were constructed to examine death in wait-listed patients. Results Overall mortality on the waiting list was 24%, and cardiovascular disease was the leading cause of death (25%), followed by infections (19%) and malignant disorders (7%). By competing risk models, age older than 50 years (subhazard ratio [SHR] 1.4; 95% CI, 1.1–1.9), CCI score higher than 3 (SHR 2.8; 95% CI, 2.1–3.7), a central venous catheter (SHR 1.8; 95% CI, 1.4–2.2) and unemployed status (SHR 1.7; 95% CI, 1.3–2.2) at dialysis entry were significantly associated with mortality. When these factors were incorporated in a composite risk model, mortality risk increased significantly with increasing risk levels. Conclusion A limited number of comorbidities, easily measurable at entry to dialysis, are associated with mortality in wait-listed patients. This simple clinical assessment may help prioritize high-risk wait-listed patients for receiving an age-matched deceased donor kidney.

23 August 2022 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MMMaría Dolores Martínez-Esteban
María Dolores Martínez-Esteban
TVTeresa Vázquez-Sánchez
Teresa Vázquez-Sánchez
RPRafael Pozo-Álvarez
Rafael Pozo-Álvarez
AMAlicia Moreno-Ortiz
Alicia Moreno-Ortiz
JAJuana Alonso-Titos
Juana Alonso-Titos
DHDomingo Hernandez
Domingo Hernandez
Background: The association between cardiac complications, such as heart failure (HF), and chronic kidney disease (CKD) is well known. In this study, we examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4). Methods: This single-centre, longitudinal, retrospective study of 31 months duration involved consecutive patients with CKD and HF with a reduced ejection fraction (HFrEF) who started treatment with sacubitril/valsartan. Glomerular filtration rate (GFR), cardiovascular risk factors, proteinuria, potassium, echocardiographic parameters and admissions for heart failure were analysed. Results: The study comprised 25 patients with a median age of 73.2 ± 5.9 years. The most frequent aetiology of heart failure was ischemic heart disease. The median GFR was 29.4 ± 8.3 ml/min/1.73 m2 and the left ventricular ejection fraction (LVEF) 36.4 ± 8.9%. The GFR improved after initiating the treatment (F = 3.396, p = 0.019), as did the LVEF at one year of follow-up (p = 0.018). The number of visits to the emergency department for heart failure was also reduced. No patients needed to start renal replacement therapy. Conclusions: This study shows that sacubitril/valsartan may play a beneficial role in patients who have advanced CKD and HFrEF, with a satisfactory safety profile.

1 November 2012 in Transplantation Proceedings
Verified
Journal Article
Closed access
VLVerónica LOPEZ López
Verónica LOPEZ López
LFL. Fuentes
L. Fuentes
TJT. Jiménez
T. Jiménez
MLM. León
M. León
IGI. Garcia
I. Garcia
DHD. Hernandez
D. Hernandez

Verified
Journal Article
Open access
PDF file
DHDomingo Hernandez
Domingo Hernandez
JAJuana Alonso-Titos
Juana Alonso-Titos
TVTeresa Vázquez
Teresa Vázquez
MLMyriam Leon
Myriam Leon
ACAbelardo Caballero
Abelardo Caballero
ATArmando Torres
Armando Torres
The impact of corticosteroid withdrawal on medium-term graft histological changes in kidney transplant (KT) recipients under standard immunosuppression is uncertain. As part of an open-label, multicenter, prospective, phase IV, 24-month clinical trial (ClinicalTrials.gov, NCT02284464) in low-immunological-risk KT recipients, 105 patients were randomized, after a protocol-biopsy at 3 months, to corticosteroid continuation (CSC, n = 52) or corticosteroid withdrawal (CSW, n = 53). Both groups received tacrolimus and MMF and had another protocol-biopsy at 24 months. The acute rejection rate, including subclinical inflammation (SCI), was comparable between groups (21.2 vs. 24.5%). No patients developed dnDSA. Inflammatory and chronicity scores increased from 3 to 24 months in patients with, at baseline, no inflammation (NI) or SCI, regardless of treatment. CSW patients with SCI at 3 months had a significantly increased chronicity score at 24 months. HbA1c levels were lower in CSW patients (6.4 ± 1.2 vs. 5.7 ± 0.6%; p = 0.013) at 24 months, as was systolic blood pressure (134.2 ± 14.9 vs. 125.7 ± 15.3 mmHg; p = 0.016). Allograft function was comparable between groups and no patients died or lost their graft. An increase in chronicity scores at 2-years post-transplantation was observed in low-immunological-risk KT recipients with initial NI or SCI, but CSW may accelerate chronicity changes, especially in patients with early SCI. This strategy did, however, improve the cardiovascular profiles of patients.

14 July 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
AMAna Muñoz Montiel
Ana Muñoz Montiel
PRPedro Ruiz-Esteban
Pedro Ruiz-Esteban
ARAdolfo Doménech Del Río
Adolfo Doménech Del Río
PVPedro Valdivielso
Pedro Valdivielso
MCMiguel Ángel Sánchez Chaparro
Miguel Ángel Sánchez Chaparro
COCasilda Olveira
Casilda Olveira